Propranolol

Search ⌘K Suggest Edit Sign in Medical uses Contraindications and precautions Adverse effects Overdose and toxicity Drug interactions Pharmacology Chemistry History Society and culture References Fact-checked by Grok 4 months ago Propranolol Propranolol is a nonselective beta-adrenergic receptor antagonist, commonly known as a beta-blocker, that competitively inhibits beta-1 and beta-2 receptors to reduce heart rate, myocardial contractility, and blood pressure, thereby decreasing cardiac workload and oxygen demand.[1] Developed in the 1960s by British pharmacologist Sir James Black primarily for the treatment of angina pectoris, it was patented in 1962, approved for medical use in 1964, and first approved by the U.S. Food and Drug Administration (FDA) in 1967; it has since become one of the most widely prescribed beta-blockers worldwide and is included on the World Health Organization's Model List of Essential Medicines.[2][3] Propranolol is indicated for cardiovascular conditions such as hypertension, angina pectoris, and certain arrhythmias, as well as non-cardiovascular uses including migraine prophylaxis, essential tremor, and infantile hemangiomas; off-label applications include anxiety (particularly situational and performance anxiety, where it mitigates physical symptoms such as tachycardia, trembling, and sweating without causing sedation), hyperthyroidism symptoms, and postural orthostatic tachycardia syndrome (POTS).[1][4][5] It is available in oral, intravenous, and extended-release formulations and is metabolized primarily by the liver via CYP2D6 enzymes, with a half-life of 3–6 hours.[1] By nonselectively blocking beta-adrenergic receptors, propranolol decreases sympathetic stimulation on the heart and vasculature; unlike cardioselective beta-blockers, its broader action increases risks in patients with respiratory conditions but enables efficacy in neurological indications.[1][6] Chemically, propranolol hydrochloride is a stable, white crystalline solid with the molecular formula C16H22ClNO2 and a molecular weight of 295.80, readily soluble in water and ethanol.[7][8] Propranolol is contraindicated in severe bradycardia, heart block, cardiogenic shock, decompensated heart failure, asthma, and severe COPD due to risks of bronchospasm and masking hypoglycemia.[1] Common adverse effects include fatigue and bradycardia; serious risks involve heart failure exacerbation and depression. Abrupt discontinuation may cause rebound effects, and overdose requires supportive care.[1][4] Medical uses Cardiovascular indications Propranolol is primarily used in the treatment of hypertension, where it reduces heart rate and cardiac output through non-selective beta-adrenergic blockade, thereby lowering blood pressure.[1] This effect is achieved by decreasing sympathetic stimulation on the heart, with typical oral dosing starting at 80 mg daily and titrated up to 640 mg daily as needed for maintenance therapy.[9] In the management of angina pectoris, propranolol blocks beta-adrenergic receptors to reduce myocardial oxygen demand by limiting increases in heart rate and contractility during stress.[1] It is indicated for long-term prophylaxis, with an initial dose of 80 mg daily and an average maintenance dose of 160 mg daily, up to a maximum of 320 mg daily.[9] For prophylaxis of myocardial infarction in patients with prior events, propranolol has demonstrated reduced reinfarction rates and overall mortality in clinical trials. The Beta Blocker Heart Attack Trial (BHAT), a randomized, double-blind study of 3,837 patients initiated 5 to 21 days post-infarction, showed a 26% reduction in total mortality with propranolol compared to placebo over a mean follow-up of 25 months.[10] Dosing in such trials typically involved 180 to 240 mg daily in divided doses.[11] Propranolol treats cardiac arrhythmias, particularly supraventricular tachycardias (SVT), by slowing conduction through the atrioventricular node via beta-blockade. For acute control, intravenous administration of 1 to 3 mg over 1 minute is used, followed by oral maintenance dosing of 10 to 30 mg every 6 to 8 hours, titrated based on response.[1] In hypertrophic cardiomyopathy, propranolol improves symptoms such as left ventricular outflow tract obstruction by exerting a negative inotropic effect that reduces the pressure gradient across the outflow tract.[12] It is indicated at doses of 80 to 160 mg daily, often as first-line therapy for symptomatic relief.[9] Propranolol plays a role in portal hypertension, particularly for preventing variceal bleeding in patients with cirrhosis, by reducing portal pressure through decreased cardiac output and splanchnic vasoconstriction.[13] Randomized trials have shown it significantly lowers the incidence of first variceal hemorrhage, with effective non-selective beta-blockade achieved at doses titrated to achieve a 25% reduction in resting heart rate, typically 40 to 160 mg twice daily.[14] Postural orthostatic tachycardia syndrome Propranolol is used off-label in the treatment of postural orthostatic tachycardia syndrome (POTS), particularly in patients with prominent tachycardia upon standing. Low doses (typically 10–20 mg) have been shown to acutely attenuate orthostatic increases in heart rate and improve symptoms such as palpitations, tremulousness, lightheadedness, and shakiness, with effects beginning within 1–2 hours.[15] When starting propranolol for POTS, patients may notice reduced heart rate increases upon standing, fewer palpitations, and some improvement in symptoms like lightheadedness or shakiness within the first few days, as the medication can begin working within hours to a day (low doses often effective quickly). However, common initial side effects include fatigue/tiredness, dizziness, cold hands and feet, slower overall heart rate, and possible gastrointestinal upset as the body adjusts. Start with a low dose to minimize side effects; individual responses vary, and full benefits may take longer. Consult a doctor for personalized advice.[16] Psychiatric indications Propranolol, a non-selective beta-blocker, is used in psychiatric practice primarily to manage anxiety by blocking β1 and β2 adrenergic receptors, thereby reducing sympathetic nervous system activation that manifests as peripheral symptoms such as tachycardia and tremor.[17] This mechanism attenuates the physiological components of anxiety without substantially altering cognitive aspects, as propranolol's anxiolytic effects are predominantly peripheral despite its lipophilic nature allowing some penetration of the blood-brain barrier.[18] Limited central nervous system effects contribute to its utility in situational anxiety, where it targets autonomic arousal rather than core emotional processing.[19] In performance anxiety, commonly known as stage fright, propranolol is employed off-label to diminish physical symptoms like rapid heartbeat and shaking, enabling individuals to perform more effectively in high-pressure situations such as public speaking or musical performances, though recent reviews indicate insufficient high-quality evidence for efficacy in anxiety disorders. Low doses (5-10 mg), commonly used for situational anxiety, are associated with minimal or no impairment in psychomotor performance and driving in most individuals, although some may experience dizziness, fatigue, or decreased alertness, warranting caution when driving or operating vehicles. Studies have shown mild decrements in psychomotor performance primarily at higher doses (e.g., 40 mg). Typical acute dosing ranges from 5 to 40 mg, administered 30 to 60 minutes prior to the event, which may control these symptoms without sedation.[20][21][22][23] For situational and performance anxiety, immediate-release propranolol is commonly taken as-needed at doses of 10-40 mg approximately 30-90 minutes before the triggering event. Noticeable reduction in physical symptoms such as tachycardia, trembling, and sweating typically begins within 30 to 60 minutes after ingestion, aligning with the drug's rapid onset of beta-blockade effects, though peak plasma concentrations and maximal effects occur 1-4 hours post-dose. This timing allows it to mitigate the physical manifestations of anxiety without significantly affecting cognitive function. Beta-blockers (e.g., propranolol) are commonly prescribed off-label for situational or performance anxiety to reduce physical symptoms like racing heart, trembling, and sweating, providing rapid relief without sedation. Nicotine may temporarily relieve anxiety but often worsens it long-term, is addictive, and is not a recommended treatment. No direct medical guidelines recommend beta-blockers specifically as a substitute for nicotine, but they offer a safer, evidence-based option for managing certain anxiety symptoms under physician supervision; consult a doctor rather than self-medicating.[24][25][26] For specific phobias, such as fear of flying or heights, propranolol aids in exposure-based therapies by blunting the heightened physiological responses during fear provocation, thereby facilitating habituation. Trials have demonstrated that propranolol administration during memory reactivation reduces subsequent arousal markers like heart rate and skin conductance in phobic individuals, enhancing the outcomes of behavioral interventions.[27] This approach is particularly useful for situational phobias, where a single dose timed to exposure sessions can lower the intensity of autonomic reactions without interfering with cognitive exposure elements. Off-label use of propranolol in post-traumatic stress disorder (PTSD) leverages its potential to disrupt fear memory reconsolidation, a process where reactivated traumatic memories become labile and susceptible to modification. In reconsolidation blockade protocols, propranolol is administered shortly after trauma script reactivation, weakening the emotional strength of the memory trace and reducing PTSD symptoms such as hyperarousal and intrusive recollections.[28] Multiple studies, including randomized controlled trials, have shown durable reductions in PTSD severity, with effect sizes indicating up to 39% symptom improvement over placebo in targeted fear responses. A 2025 systematic review and meta-analysis further supports its efficacy, showing significant improvement in PTSD symptoms compared to placebo.[29][30] However, a 2025 systematic review and meta-analysis by Archer et al. found no significant efficacy of propranolol for social phobia or panic disorder compared to placebo or benzodiazepines, underscoring that earlier enthusiasm for these applications may be overstated due to limited high-quality evidence.[23] This review, encompassing trials up to 2024, highlights the need for caution in extending propranolol beyond well-supported situational uses, as benefits in broader anxiety disorders remain unsubstantiated.[31] Other indications Propranolol is indicated for the prophylaxis of common migraine headaches, where it helps prevent attacks by stabilizing neuronal excitability and modulating vascular tone through non-selective beta-adrenergic blockade.[32] This use is supported by clinical evidence showing reduced frequency and severity of migraines in responsive patients.[1] In the treatment of essential tremor, propranolol reduces the amplitude of limb tremors primarily by blocking beta-2 adrenergic receptors in skeletal muscle, thereby dampening excessive oscillatory activity.[33] It is particularly effective for upper extremity tremors and is considered a first-line therapy for this condition.[1] For hyperthyroidism, propranolol serves as an adjunctive therapy to manage peripheral symptoms such as palpitations, tremor, and heat intolerance by antagonizing the catecholamine-mediated effects of excess thyroid hormone.[34] It does not alter thyroid hormone levels but provides symptomatic relief until definitive treatments like antithyroid drugs or surgery take effect.[33] Propranolol is FDA-approved for the treatment of proliferating infantile hemangiomas, where oral administration promotes regression of these benign vascular tumors through initial microvascular vasoconstriction—resulting in pallor and softening within 1-3 days—followed by dose-dependent anti-angiogenic inhibition and apoptosis of capillary endothelial cells.[35] The standard target dose is 3 mg/kg/day of propranolol base (approximately 3.4 mg/kg/day hydrochloride), divided into 2-3 doses and continued for 6 months, achieving significant regression in over 90% of cases per randomized controlled trial.[36] Lower doses (1-1.5 mg/kg/day) are effective in mild to moderate cases with fewer adverse effects (e.g., <5% hypoglycemia incidence and transient bradycardia) but yield slower responses and less regression in severe or high-risk hemangiomas.[37] Doses of 2-3 mg/kg/day demonstrate superiority over lower doses for 6-12 month resolution, with greater reductions in size and color due to more intense early vasoconstriction; rapid up-titration to 2 mg/kg/day does not increase adverse events.[38] In cases of treatment failure, escalation to doses >3 mg/kg/day (up to 4 mg/kg/day) may enhance efficacy but elevates risks such as hypotension and bronchospasm. Clinical studies demonstrate high efficacy in reducing lesion size and volume, especially when initiated early in the proliferative phase.[39] Small-scale studies suggest potential off-label benefits of propranolol in reducing aggressive behavior associated with dementia or autism spectrum disorder, attributed to its inhibition of sympathetic nervous system hyperactivity and resultant calming of agitation.[40] For instance, pilot trials in autism have shown decreased aggression and self-injurious behaviors, though larger randomized controlled trials are needed to confirm these effects.[41] Propranolol has been used off-label in the management of acute cardiovascular toxicity, including elevated heart rate and blood pressure, in cases of amphetamine overdose. As a non-selective beta-blocker, it can mitigate some hyperadrenergic effects of amphetamines by blocking beta-adrenergic receptors, thereby helping to control tachycardia and hypertension. Systematic reviews have reported the safety and efficacy of beta-blockers for these symptoms in amphetamine-related toxicity, though combined use or administration in overdose scenarios requires medical supervision due to potential risks and individual patient factors.[42] Dosage forms and administration Propranolol is available in several dosage forms, including immediate-release oral tablets in strengths of 10 mg, 20 mg, 40 mg, 60 mg, and 80 mg; extended-release oral capsules in strengths of 60 mg, 80 mg, 120 mg, and 160 mg; oral solutions, such as the 4.28 mg/mL formulation approved for infantile hemangiomas; and injectable solutions containing 1 mg/mL for intravenous use.[32][8][43][44] Administration is primarily oral for chronic conditions, with tablets and capsules taken with or without food, though extended-release forms should be swallowed whole and not crushed. Intravenous administration is reserved for acute situations, such as arrhythmias or hypertensive emergencies, where 1–3 mg is given slowly at a rate not exceeding 1 mg per minute under cardiac monitoring, with subsequent doses spaced at least 2 minutes apart if needed and no further dosing within 4 hours.[32][8][44] Oral solutions for hemangiomas are administered directly into the mouth using a provided syringe, preferably during or after feeding, with doses spaced at least 9 hours apart.[43] Dosing is individualized based on indication and response; for hypertension, immediate-release forms typically start at 40 mg twice daily, titrated up to a maximum of 320 mg daily in divided doses, while extended-release starts at 80 mg once daily. For situational anxiety, 10–40 mg is taken orally 1 hour prior to the event. For migraine prophylaxis, the typical initial dose is 40-80 mg per day, taken 2-3 times daily (immediate-release) or 80 mg once daily (extended-release), gradually increasing to a maintenance dose of 160-240 mg/day as needed. Dosing should involve consistent daily intake at evenly spaced intervals (multiple doses throughout the day for immediate-release; once daily, often at bedtime initially for extended-release) to maintain effectiveness. If a dose is missed, take it as soon as remembered unless it is near the next dose (then skip and resume the regular schedule); do not double doses.[45][46][32][47] In adult indications, low doses (10-40 mg/day) for essential tremor, migraine prophylaxis, and anxiety primarily target central and cardiac effects with minimal peripheral vasoconstriction, whereas medium to high doses (80-320 mg/day) for hypertension, angina, and arrhythmias involve greater β2 blockade, leading to clinically relevant peripheral microvascular vasoconstriction (e.g., cold extremities in 10-20% of patients). This effect is more pronounced with non-selective beta-blockers like propranolol compared to selective agents (e.g., atenolol, bisoprolol), with dose-dependent incidence particularly above 160 mg/day. The dose-response curve for β blockade is sigmoidal, plateauing at therapeutic levels, while peripheral vasoconstrictive effects intensify with increasing dose and non-selectivity. Guidelines recommend gradual titration with monitoring of ECG, blood pressure, and glycemia to balance benefits and risks.[1][46][48] Pharmacokinetic factors influence dosing frequency, as immediate-release formulations have a half-life of 3–6 hours and bioavailability of about 25% due to first-pass metabolism, necessitating twice- or three-times-daily administration for steady effects, whereas extended-release forms provide a longer half-life of approximately 10 hours for once-daily dosing.[32][8] In special populations, dosing adjustments are recommended; elderly patients may require lower initial doses due to reduced clearance and prolonged half-life (up to 11 hours), and those with hepatic impairment should start at reduced doses with careful titration, as bioavailability can increase threefold in cirrhosis.[32][8] Contraindications and precautions Contraindications Propranolol is contraindicated in patients with cardiogenic shock, as its negative inotropic effects can severely compromise cardiac output and exacerbate hemodynamic instability.[32] It is also absolutely contraindicated in decompensated heart failure, where beta-blockade may worsen ventricular function and lead to further deterioration.[4] The drug must not be used in individuals with severe bradycardia (heart rate less than 60 beats per minute) or sinus bradycardia, due to its inherent bradycardic effects that can precipitate life-threatening hypoperfusion.[1] Propranolol is contraindicated in second- or third-degree atrioventricular (AV) block without a functioning pacemaker, as it can further impair cardiac conduction and result in asystole.[4] Similarly, sick sinus syndrome without pacemaker support prohibits its use, given the heightened risk of profound sinus node dysfunction under beta-blockade.[4] In patients with severe asthma or chronic obstructive pulmonary disease (COPD) accompanied by a history of bronchospasm, propranolol is contraindicated because its non-selective beta-2 receptor blockade can induce bronchoconstriction and respiratory compromise.[32] Propranolol is contraindicated in patients with cocaine toxicity or recent cocaine use, as it may cause unopposed alpha-adrenergic effects leading to severe hypertension and coronary vasoconstriction.[49] Finally, known hypersensitivity to propranolol or other beta-blockers represents an absolute contraindication, owing to the potential for severe allergic reactions upon administration.[32] Precautions and monitoring Patients with diabetes mellitus or at risk of hypoglycemia require caution when prescribed propranolol, as it can mask the adrenergic symptoms of hypoglycemia, including tachycardia, tremor, and sweating, potentially delaying recognition and treatment of low blood sugar episodes.[1] Propranolol may also contribute to or prolong hypoglycemic episodes, even in non-diabetics such as during fasting or in infants, by inhibiting beta-2 adrenergic-mediated glycogenolysis, gluconeogenesis, and lipolysis, thereby impairing glucose recovery; documented cases include non-diabetic infants treated for infantile hemangiomas.[50][4] To mitigate these risks, more frequent blood glucose monitoring is advised, particularly in diabetic patients or vulnerable populations on propranolol therapy.[1] In individuals with peripheral vascular disease, propranolol should be used cautiously due to the potential for exacerbation of intermittent claudication symptoms, resulting from unopposed alpha-adrenergic vasoconstriction following beta-2 receptor blockade.[51] Although some studies indicate no significant worsening of walking distance or blood flow in mild to moderate cases, close observation for circulatory changes is recommended. For patients with hepatic impairment, dose reductions are necessary because propranolol undergoes extensive first-pass hepatic metabolism, leading to prolonged half-life and increased risk of toxicity; liver function tests should be monitored regularly.[1] In renal impairment, while no routine dose adjustment is typically required due to minimal renal excretion of unchanged drug, caution is still warranted, particularly in severe cases, with monitoring for accumulation of metabolites.[52] Abrupt withdrawal of propranolol after chronic daily use (over weeks, months, or years) may precipitate a withdrawal syndrome due to upregulated beta-adrenergic sensitivity or beta-receptor hypersensitivity, with symptoms typically appearing 1-7 days after discontinuation and resolving in 1-2 weeks.[53] Common symptoms include increased heart rate (tachycardia) and palpitations; rebound hypertension; tremors or shaking and sweating; anxiety, nervousness, or rebound worsening of original symptoms; headache; and chest pain or exacerbation of angina.[54] Serious risks, though less common, include unstable angina, myocardial infarction, arrhythmias, or sudden death, particularly in patients with cardiovascular conditions; risks may be higher with propranolol compared to some selective beta-blockers, especially after higher doses or longer durations.[55] This risk arises primarily from prolonged beta-blockade leading to receptor adaptation, as observed in studies and case reports of extended therapy; the drug's relatively short half-life (3-6 hours for immediate-release formulations) enables quick clearance without significant upregulation during occasional or as-needed dosing.[56][57] Medical guidelines recommend gradual dose tapering over 1 to 2 weeks to minimize these risks.[58] Baseline assessments and ongoing monitoring are essential for patients on propranolol, including regular checks of blood pressure, heart rate, and respiratory function to detect bradycardia, hypotension, or bronchospasm early.[1] In at-risk individuals, such as those with cardiovascular comorbidities, electrocardiogram (ECG) monitoring is advised to evaluate for conduction abnormalities or arrhythmias.[59] Propranolol may cause dizziness, fatigue, or decreased alertness in some patients, which could impair the ability to drive or operate vehicles and machinery. In patients using low doses (5-10 mg) commonly prescribed for situational anxiety, the effects on driving performance are typically minimal or absent in most individuals, as studies indicate only mild decrements in psychomotor performance at higher doses (e.g., 40 mg) and no significant impairment at lower doses. However, individual responses vary, and some may experience symptoms affecting coordination or concentration; therefore, caution is recommended when driving or operating machinery, and these activities should be avoided if such effects occur.[21][20] Adverse effects Common adverse effects Propranolol, as a non-selective beta-blocker, commonly produces mild adverse effects related to its blockade of beta-adrenergic receptors, which can reduce cardiac output and affect peripheral circulation. Fatigue and lethargy are among the most frequently reported, affecting 1% to 10% of patients, primarily due to decreased cardiac output and reduced sympathetic drive. These symptoms are often transient but may contribute to overall reduced energy levels during treatment.[60] Cardiovascular effects such as bradycardia and hypotension are also prevalent, with heart rates frequently dropping below 60 beats per minute in routine use, particularly at higher doses. These changes result from propranolol's inhibition of beta-1 receptors in the heart, leading to slowed conduction and lowered blood pressure. Patients may experience lightheadedness or dizziness as a consequence.[6] Gastrointestinal side effects include nausea, vomiting, diarrhea, constipation, abdominal pain/cramping, and epigastric distress. These are generally uncommon to common, with frequencies often reported as 1% to 10% in some sources, though many prescribing information documents do not provide specific percentages and describe them as transient or dose-related. In clinical trials, specific incidences are low (e.g., nausea ~2-3%, diarrhea ~2-3% in some hypertension studies), and they are not among the most frequent adverse effects. They are thought to arise from beta-2 receptor blockade in the gut, altering motility.[60] Cold extremities, manifesting as numbness or coolness in the hands and feet, are another common complaint, stemming from peripheral vasoconstriction due to unopposed alpha-adrenergic activity. Sleep disturbances, such as insomnia or vivid dreams, affect a notable portion of patients owing to the drug's lipophilicity and minor penetration into the central nervous system. Sexual dysfunction, particularly impotence in males, is linked to propranolol's beta-blockade effects on vascular smooth muscle, impairing penile blood flow and erectile function; this issue is reported in clinical settings and may resolve upon dose adjustment or discontinuation.[6] Serious adverse effects Propranolol, a non-selective beta-adrenergic blocker, can precipitate serious adverse effects in certain patients, particularly those with underlying vulnerabilities, due to its blockade of beta-1 and beta-2 receptors. These effects, though infrequent, may require immediate medical intervention and discontinuation of the drug.[1] In susceptible individuals, such as those with asthma, chronic obstructive pulmonary disease, or even no prior respiratory history, propranolol can induce bronchospasm by antagonizing beta-2 receptors in bronchial smooth muscle, leading to acute respiratory distress characterized by wheezing, dyspnea, and potential respiratory failure. This reaction has been documented in case reports where patients developed severe bronchoconstriction shortly after initiation or dose increase, necessitating bronchodilators or hospitalization.[61][62] Patients with marginal cardiac reserve, including those with compensated heart failure or recent myocardial infarction, face a risk of heart failure exacerbation from propranolol's negative inotropic and chronotropic effects, which reduce cardiac output and worsen fluid retention. Symptoms may include shortness of breath, peripheral edema, and pulmonary congestion, with studies indicating higher incidence in decompensated states.[60][63] Rare central nervous system effects, attributable to propranolol's high lipophilicity allowing blood-brain barrier penetration, include hallucinations and severe depression, which can manifest as visual or auditory disturbances, mood alterations, or psychotic episodes. These neuropsychiatric reactions occur in less than 0.1% of patients but may resolve upon drug withdrawal.[60][64][18] Propranolol can mask the adrenergic symptoms of hypoglycemia (e.g., tachycardia, tremors), leading to unawareness and progression to severe episodes with seizures or coma, as beta-blockade impairs counterregulatory responses. Additionally, non-selective beta-blockers like propranolol can prolong or worsen low blood sugar episodes by blunting beta-2 mediated glycogenolysis and gluconeogenesis, delaying glucose recovery even in non-diabetic individuals.[65][66] This risk is heightened in insulin-dependent individuals, with clinical assessments showing altered symptom thresholds during hypoglycemic events.[67][68] Propranolol may worsen Raynaud's phenomenon in predisposed patients by promoting vasoconstriction through unopposed alpha-adrenergic activity, resulting in severe peripheral ischemia with painful digital blanching, ulceration, or gangrene in extreme cases. This effect is more common with non-selective agents like propranolol compared to selective beta-1 blockers.[60][69][70] Use in pregnancy and lactation Risk Summary: There are no adequate and well-controlled studies in pregnant women. Beta-blockers, including propranolol, have been associated with reports of bradycardia, hypoglycemia, and respiratory depression in neonates whose mothers received the drug near delivery. Inconsistent reports of intrauterine growth restriction have been noted.[71] It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, particularly for conditions like maternal hypertension where alternatives may not be suitable.[71] Propranolol readily crosses the placenta, with cord blood concentrations typically around 30-50% of maternal plasma levels, allowing significant fetal exposure.[72] In utero exposure to propranolol has been associated with potential neonatal effects, including bradycardia, hypoglycemia, and respiratory depression, particularly in newborns whose mothers received the drug near delivery.[71] These effects arise due to the drug's beta-blocking properties impacting fetal cardiovascular and metabolic function, though not all exposed infants experience symptoms.[73] Reports of intrauterine growth restriction and prolonged labor have also been noted in some cases, underscoring the need for close fetal monitoring during use.[71] During lactation, propranolol is excreted into breast milk in low amounts, with the relative infant dose estimated at less than 1% of the maternal weight-adjusted dose, posing minimal risk to most breastfed infants.[74] It is generally considered compatible with breastfeeding, but infants should be monitored for signs of beta-blockade such as bradycardia or lethargy, especially in preterm or compromised neonates.[74] Alternatives like labetalol are often preferred in pregnancy over propranolol due to its more favorable profile for uteroplacental blood flow and lower association with fetal growth restriction.[75] Propranolol may still be indicated when its specific non-selective beta-blocking effects are required, such as for certain arrhythmias.[75] Overdose and toxicity Symptoms of overdose Propranolol overdose typically occurs with oral ingestion exceeding 2 g, which can lead to severe life-threatening toxicity due to its non-selective beta-adrenergic blockade and membrane-stabilizing effects.[76][1] Symptoms generally manifest within 1-2 hours of ingestion, though delayed onset may occur with sustained-release formulations.[77] The primary cardiovascular manifestations include severe bradycardia and hypotension, resulting from excessive inhibition of beta-1 receptors in the heart, which reduces myocardial contractility and cardiac output, potentially progressing to cardiogenic shock.[77] Cardiac conduction abnormalities, such as atrioventricular (AV) block or asystole, may also develop due to impaired sinoatrial and AV nodal function.[78] Respiratory effects in propranolol overdose stem from its non-selective beta-blockade, causing bronchospasm and potential respiratory failure, particularly in patients with underlying pulmonary conditions.[1] Central nervous system depression is prominent, especially given propranolol's high lipophilicity, which allows it to cross the blood-brain barrier readily; this can present as seizures, altered mental status, coma, or hypoglycemia, the latter exacerbated by beta-blockade masking adrenergic symptoms of low blood sugar.[77] Management of overdose Management of propranolol overdose begins with immediate stabilization following advanced cardiac life support (ACLS) protocols, prioritizing airway, breathing, and circulation (ABCs). Patients should receive supplemental oxygen, intravenous access, and continuous cardiac monitoring, with atropine administered for symptomatic bradycardia at doses titrated to response, often exceeding standard ACLS amounts (e.g., 0.5–1 mg IV every 3–5 minutes, up to 3 mg total).[79][77] For gastrointestinal decontamination, activated charcoal (1 g/kg orally) is recommended if ingestion occurred within 1–2 hours, particularly for sustained-release formulations, to reduce absorption; multiple doses may be considered under toxicologist guidance. Glucagon is the primary antidote for hemodynamic instability, administered as an initial intravenous bolus of 5–10 mg (or 50–150 mcg/kg) over 1–2 minutes, followed by an infusion of 1–10 mg/hour titrated to effect, as it increases intracellular cyclic adenosine monophosphate (cAMP) independently of beta-adrenergic receptors, enhancing myocardial contractility and heart rate.[77][78][80] In refractory hypotension or cardiac arrest, high-dose insulin euglycemia therapy (1 unit/kg bolus followed by 0.5–1 unit/kg/hour infusion with glucose monitoring) and vasopressors such as epinephrine (starting at 1–4 mcg/min IV, titrated upward) are employed, with epinephrine preferred due to its combined alpha- and beta-adrenergic effects. For severe cases involving lipophilic agents like propranolol, intravenous lipid emulsion (20% solution: 1.5 mL/kg bolus followed by 0.25 mL/kg/min infusion for up to 1 hour) serves as an adjunct by creating a lipid sink to sequester the drug, though its use requires toxicologist consultation due to potential complications like pancreatitis or interference with laboratory assays.[79][77][81] Hemodialysis and hemoperfusion are ineffective for propranolol removal owing to its high protein binding (approximately 90%) and extensive tissue distribution, though they may be considered for co-ingestants like sotalol. Patients with significant toxicity warrant intensive care unit (ICU) admission for continuous electrocardiogram (ECG) monitoring, serial blood pressure assessments via arterial line, and supportive measures including mechanical ventilation if needed, with observation for at least 24 hours in cases of large ingestions.[79][77] Drug interactions Pharmacodynamic interactions Propranolol, a non-selective beta-adrenergic receptor blocker, exhibits pharmacodynamic interactions with various medications that arise from shared effects on cardiac conduction, metabolic responses, or vascular tone, potentially amplifying therapeutic or adverse outcomes. These interactions occur at the receptor or physiological level without altering drug concentrations.[1] Concomitant use of propranolol with other beta-blockers can lead to additive bradycardia due to cumulative blockade of beta-1 receptors in the sinoatrial node, slowing heart rate beyond the effect of either agent alone. Similarly, combination with non-dihydropyridine calcium channel blockers, such as verapamil, enhances negative chronotropic and dromotropic effects on the atrioventricular (AV) node, increasing the risk of profound bradycardia and AV block; this interaction stems from synergistic suppression of cardiac conduction and is particularly hazardous in patients with pre-existing conduction abnormalities. Propranolol also potentiates the bradycardic effects of digoxin by further depressing AV nodal function through independent mechanisms of beta-blockade and digitalis-induced vagal stimulation.[82][83][1] In patients with diabetes, propranolol can exacerbate hypoglycemia induced by insulin or oral antidiabetic agents like sulfonylureas, as it inhibits the counter-regulatory release of glucose from glycogenolysis and gluconeogenesis via beta-2 receptor blockade; moreover, by blunting the tachycardic response to low blood sugar, it masks a key symptomatic warning sign, potentially delaying recognition and treatment of hypoglycemic episodes.[84][68][1] Propranolol antagonizes the bronchodilatory action of beta-2 agonists such as albuterol in individuals with asthma or chronic obstructive pulmonary disease, as its non-selective blockade of beta-2 receptors in bronchial smooth muscle counteracts agonist-induced relaxation, thereby worsening bronchospasm and respiratory distress during acute exacerbations.[85][1] Nonsteroidal anti-inflammatory drugs (NSAIDs), including ibuprofen, can diminish the antihypertensive efficacy of propranolol by promoting vasoconstriction through inhibition of prostaglandin synthesis, which normally facilitates vasodilation; this counteracts the beta-blocker's reduction in cardiac output and peripheral resistance, leading to attenuated blood pressure control.[86][87][1] Additionally, co-administration of propranolol with antiarrhythmic agents like amiodarone results in synergistic AV nodal depression, heightening the risk of high-degree AV block due to combined effects on potassium channels, beta-receptors, and calcium influx, necessitating close electrocardiographic monitoring.[82][1] Chlordiazepoxide and propranolol exhibit a moderate pharmacodynamic interaction due to additive effects in lowering blood pressure, potentially causing symptoms such as headache, dizziness, lightheadedness, fainting, or changes in pulse or heart rate. These effects are more likely at treatment initiation, dose increases, or restarts. Chlordiazepoxide is approved for the management of anxiety disorders, while propranolol is used off-label for anxiety and panic disorder (off-label for both in panic disorder). Patients should be monitored for hypotensive symptoms, avoid sudden position changes, and consult a doctor before combining. No severe contraindications are noted, but use under medical supervision is recommended.[88] Lorazepam and propranolol exhibit a minor pharmacodynamic interaction due to additive central nervous system depressant and cardiovascular effects, potentially resulting in increased drowsiness, dizziness, low blood pressure, or slowed heart rate. Propranolol does not significantly affect the metabolism or clearance of lorazepam, indicating no notable pharmacokinetic interaction. Lorazepam is approved for the short-term relief of anxiety symptoms related to anxiety disorders and anxiety associated with depressive symptoms, while propranolol is used off-label for situational anxiety and performance anxiety. Patients should consult a healthcare provider before taking them together, as monitoring or dose adjustments may be needed.[89][90] Methylphenidate and propranolol exhibit a moderate pharmacodynamic interaction. Methylphenidate, a central nervous system stimulant, may increase blood pressure and heart rate through its sympathomimetic activity, potentially diminishing the antihypertensive and heart rate-lowering effects of propranolol via pharmacodynamic antagonism. This can lead to reduced efficacy of propranolol in controlling blood pressure. Use with caution; monitor blood pressure closely, adjust propranolol dosage if necessary, and consult a healthcare provider before combining these medications.[91] Amphetamine (amfetamine is the INN and European spelling) and propranolol have no major reported pharmacodynamic interactions. Propranolol may block some hyperactive effects of amphetamines, as shown in preclinical studies implicating beta-adrenergic mechanisms. Propranolol has also been used to manage acute cardiovascular toxicity (such as eleva